Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease by  et al.
                                                              
University of Dundee
Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary
disease
Huang, Jeffrey T. J.; Bolton, Charlotte E.; Miller, Bruce E.; Tal-Singer, Ruth; Rabinovich,
Roberto A.; Palmer, Colin N. A.; Thomson, Neil C.; MacNee, William; the Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators
Published in:
European Respiratory Journal
DOI:
10.1183/13993003.01125-2016
Publication date:
2016
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Huang, J. T. J., Bolton, C. E., Miller, B. E., Tal-Singer, R., Rabinovich, R. A., Palmer, C. N. A., ... the Evaluation
of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators (2016). Age-
dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. European Respiratory
Journal, 48(4), 1215-1218. DOI: 10.1183/13993003.01125-2016
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Age-dependent elastin degradation is enhanced in chronic 
obstructive pulmonary disease 
Journal: European Respiratory Journal 
Manuscript ID ERJ-01125-2016.R1 
Manuscript Type: Research Letter 
Date Submitted by the Author: n/a 
Complete List of Authors: Huang, Jeffrey; University of Dundee, School of Medicine 
Bolton, Charlotte; University of Nottingham, NIHR Nottingham Respiratory 
BRU 
Miller, Bruce; GlaxoSMithKline, Respiratory Discovery Medicine 
Tal-Singer, Ruth; GlaxoSmithKline, COPD Drug Discovery 
Rabinovich, Roberto; The University of Edinburgh, ELEGI Laboratory, 
MRC/University of Edinburgh Centre for Inflammation Research; Hospital 
Clinic - Barcelona, Servei de Pneumolog 
Palmer, Colin; University of Dundee, Biomedical Research Institute 
Thomson, Neil; University of Glasgow, Institute of Infection, Immunity & 
Inflammation 
MacNee, William; Colt Research Laboratories, Medical School 
Key Words: desmosine, COPD, ageing, elastin degradation 
European Respiratory Journal
 “This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for 
publication in the European Respiratory Journal, prior to copy-editing, formatting and 
typesetting. This version of the manuscript may not be duplicated or reproduced without prior 
permission from the copyright owner, the European Respiratory Society. The publisher is not 
responsible or liable for any errors or omissions in this version of the manuscript or in any 
version derived from it by any other parties. The final, copy-edited, published article, which is the 
version of record, is available without a subscription 18 months after the date of issue 
publication.”
 1
Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease 
Jeffrey T.J. Huang
1
, Charlotte E. Bolton
2
, Bruce E. Miller
3
, Ruth Tal-Singer
3
, Roberto A. 
Rabinovich
4
, Colin Palmer
1
, Neil C.Thomson
5
 and William MacNee
4
; Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. 
 
1. School of Medicine, University of Dundee, Dundee DD1 9SY 
2. Nottingham Respiratory Research Unit, School of Medicine, University of 
Nottingham, Nottingham, UK; 
3. Respiratory Therapy Area Unit, GSK, King of Prussia, Pennsylvania, USA; 
4. MRC / University of Edinburgh Centre for Inflammation Research , Queen’s Medical 
Research Institute  47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK 
5. Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK 
 
*Corresponding author: Jeffrey T.-J. Huang PhD; School of Medicine, University of Dundee, 
Dundee, DD1 9SY 
Tel: +44 (0)1382 386901; E-mail: j.t.j.huang@dundee.ac.uk 
 
Abbreviation: COPD: Chronic obstructive pulmonary disease, DES/IDES: desmosine and 
isodesmosine 
 
Abstract 
Elastin turnover increases with chronological age and COPD accelerates this process beyond 
normal ageing. 
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To the Editor, 
Chronic obstructive pulmonary disease (COPD) is primarily a lung condition characterized by 
the presence of persistent airflow limitation resulting from inflammation, remodeling of 
small airways, and emphysema. It is well-recognized that the impacts of COPD extend 
beyond the lung with many patients suffering systemic manifestations such as 
cardiovascular diseases that affect morbidity and mortality[1]. “Accelerated ageing” has 
been proposed as a mechanism that underlies many of the pulmonary and extra-pulmonary 
consequences of COPD[2, 3]. It is thought that a decline in organ function is a feature of 
ageing in response to the accumulation of cell and molecular damage, and in the case of 
COPD, noxious inhalants such as tobacco smoke increase this damage, thus accelerating the 
ageing process, leading to the development of COPD. With the exception of lung function 
decline, however, evidence indicating that tobacco smoking or COPD accelerates age-
associated deterioration remain scarce. 
The degradation of elastin, a key protein component of connective tissues that critically 
provides the characteristics of elasticity, resilience, and deformability, is an important 
feature in normal ageing and in COPD. Elastin has a long half-life (~74 years[4]) in contrast to 
minutes to days for  most intracellular proteins[5]. This longevity increases its susceptibility 
to oxidative and chemical damage, which are believed to drive age-related elastic fiber 
turnover associated with low-grade chronic inflammation. This turnover can be measured 
by the levels of circulating desmosine and isodesmosine (DES/IDES), two crosslinking 
moieties that specifically exist in mature elastin[6]. We and others have shown increased 
circulating DES/IDES levels in COPD patients in comparison to healthy smokers and never-
smokers[7-10]. Recently, we further demonstrated that this increase was associated with 
higher mortality and cardiovascular morbidity in a large cohort study[10]. Interestingly, 
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among all of the demographic variables analyzed, circulating DES/IDES levels display the 
strongest and consistent correlation with chronological age in three independent cohorts of 
COPD patients[10, 11]. This marker also showed a stronger association with age than 
inflammatory markers (e.g. fibrinogen, Clara cell secretary protein 18, and high sensitivity C 
reactive peptide)
10
. These observations raise the possibility that systemic elastin turnover is 
an age-dependent process, and that COPD and smoking can alter the rate of this process.  
To test the hypothesis, we analyzed data collected from three study cohorts previously 
described
10,11
 comprising 261 never-smoker controls, 380 smoker controls, and 1,332 COPD 
patients. The relationship between circulating DES/IDES levels and age was analyzed 
separately in each group. Consistent with the observations from previous studies[10-12], we 
confirmed that circulating DES/IDES levels were significantly correlated with age in all 
groups (p<0.0001, Figure 1A). The correlation was weaker in the smoker control group 
compared to the never-smoker control or COPD group (r=0.41, 0.28, and 0.41, for never-
smoker control, smoker control and COPD groups, respectively, p<0.0001 for all groups). 
The positive associations remain highly significant taking into account gender, FEV1 or pack-
years smoking history (p<0.0001). 
To investigate whether the COPD or smoker control group has a higher age-associated 
increase in elastin turnover, we compared the slopes of the regression lines between the 
three groups using a linear mixed effect model incorporating subject-specific random effect, 
and taking into account of the effect of two visits from some individuals. We found that the 
slope of elastin turnover to age regression was greater in COPD patients (6.6ng/L per year) 
compared to never-smokers (2.9 ng/L per year, p<0.0001) or smokers (3.1 ng/L per year, 
p<0.0001, Figure 1B). Further subgroup analysis indicates that smoking status, or its 
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interaction with age in the COPD group had no significant effect on circulating DES/IDES 
levels (p=0.47 and 0.47, respectively).  In smoker control subjects, circulating DES/IDES 
levels were 15% higher than never-smokers (p=0.008) but no difference was found in the 
slope (p=0.68). The difference in the intercepts between smoker controls and never-smoker 
controls (~20pg/mL) suggests that smoker controls are biologically on-average 6.9 years 
older than never-smoker controls. 
These results strongly support the hypothesis that elastin turnover increases with age in 
general, and that COPD accelerates the age-dependent increase on elastin turnover. 
However, it does not suggest a greater age-related increase in smoker controls, compared 
with never-smokers. Overall, these results are in line with the general concept of 
“accelerated ageing” in COPD. 
While circulating DES/IDES can come from any elastin expressing tissue, we speculate that 
vascular system is the most predominant source due to its size and proximity to blood. The 
consequence of such elevation in elastin turnover is likely to affect the vascular physiology 
and cardiovascular outcomes. Indeed, we have shown that the increased circulating 
DES/IDES levels are associated with higher mortality and cardiovascular comorbidity in 
COPD[10]. The circulating DES/IDES levels did not, however, relate to emphysema 
progression or FEV1 decline in COPD[10], potentially due to the reasons mentioned 
previously.  
It is worth noting that circulating DES/IDES and other biomarkers of ageing such as telomere 
length are different in nature, although they are all correlated with chronological age. 
Because circulating DES/IDES levels estimate the activity of proteolytic enzymes towards 
mature elastin, it may be more relevant to ageing activity at the sampling time, whereas 
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other typical biomarkers of ageing such as telomere length may be more representative of 
the cumulative damage over time (i.e. biological age). It is possible that a biologically older 
individual can have a low ageing activity or vice versa. Thus the potential utility of these 
biomarker may be different.  From an intervention point of view, for example, it may be 
more logical to target those who are biologically young, but have higher ageing activity, than 
those who are biologically old but with low ageing activity. Conversely, it may be more 
sensible to measure biological age to determine long-term progression in response to an 
intervention. 
Quantifying circulating DES/IDES may therefore represent a potential tool for monitoring 
normal ageing and accelerated ageing, especially in a setting of therapeutic or life style 
interventions. One of example comes a study of tiotropium bromide which was shown to  
reduce plasma DES/IDES levels in a small cohort of COPD patients[13]. This drug is also 
known to be associated with a lower probability of major and fatal cardiovascular events in 
a COPD population compared to the placebo group[14].   
We acknowledge several limitations in the current study. First, we assume the circulating 
DES/IDES levels represent the rate of proteolytic enzyme activity towards mature elastin. 
The influence of renal excretion is not taken into account, although our previous analysis did 
not show an association between renal function and circulation DES/IDES levels[10]. Second, 
the control subjects were not followed up long enough to observe any meaningful clinical 
outcomes. Third, while we did not observe an age-dependent acceleration of elastin 
turnover in the smoker control group, we cannot exclude a possibility of a selection bias 
that these smokers are more resistant to the development COPD and hence enhanced 
elastin degradation with age, due to genetic or environmental factors. 
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In summary, we demonstrated that elastin turnover increases with age in never-smoker 
controls, and COPD patients. The age-related amplification is enhanced in COPD but not in 
smokers without COPD. These results suggest that early intervention in an at-risk population 
should be a priority in reducing ageing-associated morbidity and mortality. Circulating 
DES/IDES may represent a tool to monitor the rate of ageing, particularly in identifying high-
risk smokers and COPD patients. 
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FIGURE LEGENDS 
 
Figure 1.  Modeling of elastin turnover as a function to age in COPD patients, smoker and 
never-smoker controls.  
A. Scatter plots of circulating DES/IDES levels and age in never-smoker controls, smoker 
controls and patients with COPD from three cohort studies.  
B. A predicted linear mixed model of circulating DES/IDES levels as a function of age in 
never-smoker controls (in blue), smoker controls (in green) and patients with COPD 
(in red).  The equation of the regression lines are shown in the graph with dash line 
showing 95% confidence.  The correlation coefficients rho are 0.41, 0.28 and 0.41, 
for smoker, never-smoker control and COPD groups, respectively (p<0.0001). 
Page 9 of 19 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 1
Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease 
Jeffrey T.J. Huang
1
, Charlotte E. Bolton
2
, Bruce E. Miller
3
, Ruth Tal-Singer
3
, Roberto A. 
Rabinovich
4
, Colin Palmer
1
, Neil C.Thomson
5
 and William MacNee
4
; Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. 
 
1. School of Medicine, University of Dundee, Dundee DD1 9SY 
2. Nottingham Respiratory Research Unit, School of Medicine, University of 
Nottingham, Nottingham, UK; 
3. Respiratory Therapy Area Unit, GSK, King of Prussia, Pennsylvania, USA; 
4. MRC / University of Edinburgh Centre for Inflammation Research , Queen’s Medical 
Research Institute  47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK 
5. Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK 
 
*Corresponding author: Jeffrey T.-J. Huang PhD; School of Medicine, University of Dundee, 
Dundee, DD1 9SY 
Tel: +44 (0)1382 386901; E-mail: j.t.j.huang@dundee.ac.uk 
 
Abbreviation: COPD: Chronic obstructive pulmonary disease, DES/IDES: desmosine and 
isodesmosine 
 
Abstract 
Elastin turnover increases with chronological age and COPD accelerates this process beyond 
normal ageing. 
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To the Editor, 
Chronic obstructive pulmonary disease (COPD) is primarily a lung condition characterized by 
the presence of persistent airflow limitation resulting from inflammation, remodeling of 
small airways, and emphysema. It is well-recognized that the impacts of COPD extend 
beyond the lung with many patients suffering systemic manifestations such as 
cardiovascular diseases that affect morbidity and mortality[1]. “Accelerated ageing” has 
been proposed as a mechanism that underlies many of the pulmonary and extra-pulmonary 
consequences of COPD[2, 3]. It is thought that a decline in organ function is a feature of 
ageing in response to the accumulation of cell and molecular damage, and in the case of 
COPD, noxious inhalants such as tobacco smoke increase this damage, thus accelerating the 
ageing process, leading to the development of COPD. With the exception of lung function 
decline, however, evidence indicating that tobacco smoking or COPD accelerates age-
associated deterioration remain scarce. 
The degradation of elastin, a key protein component of connective tissues that critically 
provides the characteristics of elasticity, resilience, and deformability, is an important 
feature in normal ageing and in COPD. Elastin has a long half-life (~74 years[4]) in contrast to 
minutes to days for  most intracellular proteins[5]. This longevity increases its susceptibility 
to oxidative and chemical damage, which are believed to drive age-related elastic fiber 
turnover associated with low-grade chronic inflammation. This turnover can be measured 
by the levels of circulating desmosine and isodesmosine (DES/IDES), two crosslinking 
moieties that specifically exist in mature elastin[6]. We and others have shown increased 
circulating DES/IDES levels in COPD patients in comparison to healthy smokers and never-
smokers[7-10]. Recently, we further demonstrated that this increase was associated with 
higher mortality and cardiovascular morbidity in a large cohort study[10]. Interestingly, 
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among all of the demographic variables analyzed, circulating DES/IDES levels display the 
strongest and consistent correlation with chronological age in three independent cohorts of 
COPD patients[10, 11]. This marker also showed a stronger association with age than 
inflammatory markers (e.g. fibrinogen, Clara cell secretary protein 18, and high sensitivity C 
reactive peptide)
10
. These observations raise the possibility that systemic elastin turnover is 
an age-dependent process, and that COPD and smoking can alter the rate of this process.  
To test the hypothesis, we analyzed data collected from three study cohorts previously 
described
10,11
 comprising 261 never-smoker controls, 380 smoker controls, and 1,332 COPD 
patients. The relationship between circulating DES/IDES levels and age was analyzed 
separately in each group. Consistent with the observations from previous studies[10-12], we 
confirmed that circulating DES/IDES levels were significantly correlated with age in all 
groups (p<0.0001, Figure 1A). The correlation was weaker in the smoker control group 
compared to the never-smoker control or COPD group (r=0.41, 0.28, and 0.41, for never-
smoker control, smoker control and COPD groups, respectively, p<0.0001 for all groups). 
The positive associations remain highly significant taking into account gender, FEV1 or pack-
years smoking history (p<0.0001). 
To investigate whether the COPD or smoker control group has a higher age-associated 
increase in elastin turnover, we compared the slopes of the regression lines between the 
three groups using a linear mixed effect model incorporating subject-specific random effect, 
and taking into account of the effect of two visits from some individuals. We found that the 
slope of elastin turnover to age regression was greater in COPD patients (6.6ng/L per year) 
compared to never-smokers (2.9 ng/L per year, p<0.0001) or smokers (3.1 ng/L per year, 
p<0.0001, Figure 1B). Further subgroup analysis indicates that smoking status, or its 
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interaction with age in the COPD group had no significant effect on circulating DES/IDES 
levels (p=0.47 and 0.47, respectively).  In smoker control subjects, circulating DES/IDES 
levels were 15% higher than never-smokers (p=0.008) but no difference was found in the 
slope (p=0.68). The difference in the intercepts between smoker controls and never-smoker 
controls (~20pg/mL) suggests that smoker controls are biologically on-average 6.9 years 
older than never-smoker controls. 
These results strongly support the hypothesis that elastin turnover increases with age in 
general, and that COPD accelerates the age-dependent increase on elastin turnover. 
However, it does not suggest a greater age-related increase in smoker controls, compared 
with never-smokers. Overall, these results are in line with the general concept of 
“accelerated ageing” in COPD. 
While circulating DES/IDES can come from any elastin expressing tissue, we speculate that 
vascular system is the most predominant source due to its size and proximity to blood. The 
consequence of such elevation in elastin turnover is likely to affect the vascular physiology 
and cardiovascular outcomes. Indeed, we have shown that the increased circulating 
DES/IDES levels are associated with higher mortality and cardiovascular comorbidity in 
COPD[10]. The circulating DES/IDES levels did not, however, relate to emphysema 
progression or FEV1 decline in COPD[10], potentially due to the reasons mentioned 
previously.  
It is worth noting that circulating DES/IDES and other biomarkers of ageing such as telomere 
length are different in nature, although they are all correlated with chronological age. 
Because circulating DES/IDES levels estimate the activity of proteolytic enzymes towards 
mature elastin, it may be more relevant to ageing activity at the sampling time, whereas 
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other typical biomarkers of ageing such as telomere length may be more representative of 
the cumulative damage over time (i.e. biological age). It is possible that a biologically older 
individual can have a low ageing activity or vice versa. Thus the potential utility of these 
biomarker may be different.  From an intervention point of view, for example, it may be 
more logical to target those who are biologically young, but have higher ageing activity, than 
those who are biologically old but with low ageing activity. Conversely, it may be more 
sensible to measure biological age to determine long-term progression in response to an 
intervention. 
Quantifying circulating DES/IDES may therefore represent a potential tool for monitoring 
normal ageing and accelerated ageing, especially in a setting of therapeutic or life style 
interventions. One of example comes a study of tiotropium bromide which was shown to  
reduce plasma DES/IDES levels in a small cohort of COPD patients[13]. This drug is also 
known to be associated with a lower probability of major and fatal cardiovascular events in 
a COPD population compared to the placebo group[14].   
We acknowledge several limitations in the current study. First, we assume the circulating 
DES/IDES levels represent the rate of proteolytic enzyme activity towards mature elastin. 
The influence of renal excretion is not taken into account, although our previous analysis did 
not show an association between renal function and circulation DES/IDES levels[10]. Second, 
the control subjects were not followed up long enough to observe any meaningful clinical 
outcomes. Third, while we did not observe an age-dependent acceleration of elastin 
turnover in the smoker control group, we cannot exclude a possibility of a selection bias 
that these smokers are more resistant to the development COPD and hence enhanced 
elastin degradation with age, due to genetic or environmental factors. 
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In summary, we demonstrated that elastin turnover increases with age in never-smoker 
controls, and COPD patients. The age-related amplification is enhanced in COPD but not in 
smokers without COPD. These results suggest that early intervention in an at-risk population 
should be a priority in reducing ageing-associated morbidity and mortality. Circulating 
DES/IDES may represent a tool to monitor the rate of ageing, particularly in identifying high-
risk smokers and COPD patients. 
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FIGURE LEGENDS 
 
Figure 1.  Modeling of elastin turnover as a function to age in COPD patients, smoker and 
never-smoker controls.  
A. Scatter plots of circulating DES/IDES levels and age in never-smoker controls, smoker 
controls and patients with COPD from three cohort studies.  
B. A predicted linear mixed model of circulating DES/IDES levels as a function of age in 
never-smoker controls (in blue), smoker controls (in green) and patients with COPD 
(in red).  The equation of the regression lines are shown in the graph with dash line 
showing 95% confidence.  The correlation coefficients rho are 0.41, 0.28 and 0.41, 
for smoker, never-smoker control and COPD groups, respectively (p<0.0001). 
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